James Gilbaugh, MD
Urology · Wichita, KSNPI 1952389728
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,759 and has fallen 92.1% since, to $138 in 2025.
Across 177 payments — averaging $27.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$768
- Boston Scientific$617
- AbbVie$511
- Astellas Pharma US Inc$361
- Johnson & Johnson$314
- Sumitomo Pharma America, Inc.$217
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,84798%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 11 | $768 |
| Boston Scientific | 14 | $617 |
| AbbVie(2 entities) | 26 | $511 |
| Astellas Pharma US Inc | 18 | $361 |
| Johnson & Johnson | 10 | $314 |
| Sumitomo Pharma America, Inc. | 14 | $217 |
| Axonics, Inc. | 6 | $174 |
| Janssen Scientific Affairs, LLC | 2 | $168 |
| Endo Pharmaceuticals Inc. | 6 | $164 |
| Amgen | 10 | $164 |
| Ferring Pharmaceuticals Inc. | 3 | $156 |
| Pfizer | 10 | $139 |
| Progenics Pharmaceuticals, Inc. | 2 | $123 |
| Dendreon Pharmaceuticals LLC | 5 | $122 |
| Antares Pharma, Inc. | 6 | $92 |
| Procept Biorobotics Corporation | 1 | $91 |
| Neotract Inc. | 3 | $89 |
| Verity Pharmaceuticals Inc. | 2 | $87 |
| Travere Therapeutics, Inc. | 4 | $82 |
| Coloplast | 4 | $57 |
| Tolmar Pharmaceuticals, Inc. | 4 | $52 |
| Conmed Corporation | 1 | $50 |
| KARL Storz Endoscopy-america | 1 | $49 |
| Olympus America Inc. | 3 | $48 |
| Photocure Inc | 1 | $45 |
| Siemens Medical Solutions USA, Inc. | 1 | $38 |
| Merck | 2 | $35 |
| Novartis | 1 | $31 |
| Urovant Sciences Inc | 2 | $28 |
| Coopersurgical, Inc. | 1 | $25 |
| Davol Inc. | 2 | $23 |
| Blue Earth Diagnostics | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$467
- AMS 700$223
- ADSTILADRIN$129
- AMS 700 CXR RTE KIT$114
- AMS$112
- Erleada$111
- Lupron Depot$104
- PYLARIFY$101
How this compares
$4,938 in reported general payments places this provider in the 65th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 71 | $37,763 |
| MyrbetriqMirabegron | 57 | $34,484 |
| Solifenacin Succinate | 95 | $5,201 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 177 | $2,405 |
| Tamsulosin Hcl | 165 | $2,080 |
| Potassium Citrate ErPotassium Citrate | 24 | $1,642 |
| Testosterone | 11 | $1,601 |
| Estradiol | 12 | $1,495 |
| Finasteride | 195 | $1,457 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 19 | $1,316 |
| Cephalexin | 149 | $1,028 |
| Oxybutynin Chloride ErOxybutynin Chloride | 40 | $887 |
| Testosterone Cypionate | 19 | $645 |
| Methenamine Hippurate | 13 | $628 |
| Fluconazole | 33 | $385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $217 | $37,76371 claims |
| Astellas Pharma US IncMyrbetriq | $361 | $34,48457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 urology providers in Kansas.
Other urology in Wichita
- Timothy RichardsonWichita$493K
- Gregory ByrdWichita$18K
- Philippe NabboutWichita$13K
- Fadi JoudiWichita$12K
- Ayham FarhaWichita$8K
- Jeffrey DavisWichita$8K
- Jonathan JensenWichita$4K
- George ZakhariaWichita$3K
- Surendra KollaWichita$3K
- Kahlil SaadWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.